Therapeutical approaches under investigation for treatment of Chagas disease.
INTRODUCTION
A century after its discovery, American trypanosomiasis or Chagas disease remains a serious health problem in Latin America, where it affects around 7 - 8 million people. The prevalence of Chagas disease in the poorer parts of the world has meant that it has largely been neglected with limited progress that made in identifying new drugs for the treatment. The nitroheterocyclic drugs nifurtimox and benznidazole are first-line drugs available for Chagas disease with limitations that include variable efficacy, long treatment courses and toxicity.


AREAS COVERED
This review focuses on different therapeutic strategies that have been used for the discovery of new treatments for Chagas disease. These include combination chemotherapy, drug repositioning, re-dosing regimens for current drugs and the identification of new drugs with specified target profiles.


EXPERT OPINION
There are currently several reasons for a more optimistic view about chemotherapy with Chagas disease. However, despite some progress being made in preclinical studies, there is yet to be an ideal drug or formulation for human treatment. One major drawback in the evaluation of potential Chagas disease therapeutics is the lack of tools available to perform the said evaluation. Indeed, there is a great need to discover a better biomarker that could determine the efficacy of potential chemotherapeutics in treated patients.
['Bahia|Maria Terezinha|MT|', 'Diniz|Lívia de Figueiredo|Lde F|', 'Mosqueira|Vanessa Carla Furtado|VC|']
D000818:Animals D015415:Biomarkers D014355:Chagas Disease D015195:Drug Design D058492:Drug Repositioning D006801:Humans D014344:Trypanocidal Agents
Chagas disease efficacy chemotherapy Trypanosoma cruzi drug combinations nanocarriers new formulations